
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
Resistance to Ibrutinib
Author(s)John C. Byrd, MD
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
Advertisement
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
View more about the treatment of chronic lymphocytic leukemia > >
Articles in this issue
about 12 years ago
In the Pipeline: Potential New Treatments for AMLabout 12 years ago
Epidemiology in B-Cell Malignanciesabout 12 years ago
Pathogenesis of Follicular Lymphomaabout 12 years ago
IPI-145 and ABT-199 for Lymphoid Malignanciesabout 12 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
4
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
5




























